Novo Nordisk is poised to enter the market for sickle cell disease with its oral drug etavopivat, following successful Phase 3 trial results showing substantial reductions in vaso-occlusive crises and improved hemoglobin responses. The company's plans for regulatory submission in late 2026 are seen as a significant threat to rival Agios Pharmaceuticals, which has already faced declining stock prices. While Novo faces challenges in the obesity treatment space due to stiff competition from Eli Lilly, its advancements in blood disorders represent a strategic pivot and growth opportunity.
“$AGIO -16% on $NVO study outcome in sickle cell disease.”
“$AGIO (-14.7% pre) $NVO Novo Nordisk’s new pill cuts sickle cell pain crises, boosting outcomes and sending Agios Pharma shares down after strong trial results”
“Could weight loss drugs be the biggest pharma opportunity of our lifetime? Pills, lower costs, and mass production could soon unlock a much bigger market for stocks like $LLY and $NVO.”
“Novo's oral sickle cell drug etavopivat hits bullseyes in pivotal trial $NVO $AGIO”
“$NVO | Novo Nordisk reports strong late stage data for sickle cell pill, moving toward approval. Rival $AGIO drops sharply as competitive pressure increases.”
“Novo Nordisk hat starke Phase-3-Daten vorgelegt: In der HIBISCUS-Studie erreicht der orale Wirkstoff Etavopivat bei Patienten mit Sichelzellanämie beide primären Ziele klar.”
“Men don’t need GLP’s, they need discipline. Which is a scarcity now, which is why I’m bullish $NVO.”
“Big names like Novo Nordisk ($NVO) and Eli Lilly ($LLY) lead with GLP-1 peptides (Ozempic/Mounjaro).”
“NOVO NORDISK: ETAVOPIVAT IS THE FIRST IN A NEW CLASS OF DRUGS TO MEET BOTH CO-PRIMARY ENDPOINTS IN THE PHASE 3 HIBISCUS TRIAL, SUBSTANTIALLY REDUCING VASO-OCCLUSIVE CRISIS EVENTS AND IMPROVING HAEMOGLOBIN RESPONSE IN SICKLE CELL DISEASE”
“$NVO - NOVO NORDISK: ETAVOPIVAT IS THE FIRST IN A NEW CLASS OF DRUGS TO MEET BOTH CO-PRIMARY ENDPOINTS IN THE PHASE 3 HIBISCUS TRIAL, SUBSTANTIALLY REDUCING VASO-OCCLUSIVE CRISIS EVENTS AND IMPROVING HAEMOGLOBIN RESPONSE IN SICKLE CELL DISEASE.”
“Shares of Agios Pharmaceuticals took a header Monday after Novo Nordisk's rival sickle cell treatment succeeded in Phase 3 testing.”
“As such, the news from Novo, and its intent to file for FDA approval in the second half of 2026 is a clear threat to the earnings potential of Agios' mitapavit, even as it works with the FDA to 'achieve alignment on the confirmatory clinical trial required for submission.'”
